Do analysts rate BNGO or CSBR?

Bionano Genomics presently has a consensus target price of $6.00, suggesting a potential upside of 255.03%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BNGO or CSBR?

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. Bionano Genomics' average media sentiment score of 0.00 equaled Champions Oncology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Champions Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RPID or BNGO?

In the previous week, Rapid Micro Biosystems and Rapid Micro Biosystems both had 2 articles in the media. Rapid Micro Biosystems' average media sentiment score of 0.00 equaled Bionano Genomics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapid Micro Biosystems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BNGO or IBAC?

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 255.03%. Given Bionano Genomics' stronger consensus rating and higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BNGO or IBAC?

IB Acquisition has lower revenue, but higher earnings than Bionano Genomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bionano Genomics $28.51M 0.70 -$26.40M -$3.02 N/A IB Acquisition N/A N/A N/A N/A N/A

Does the media refer more to BNGO or IBAC?

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. IB Acquisition's average media sentiment score of 0.36 beat Bionano Genomics' score of 0.00 indicating that IB Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNGO or HYFT more profitable?

MindWalk has a net margin of -105.11% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -106.58% -78.78% -48.54% MindWalk -105.11% -133.26% -77.78%

Does the media refer more to BNGO or HYFT?

In the previous week, MindWalk had 5 more articles in the media than Bionano Genomics. MarketBeat recorded 7 mentions for MindWalk and 2 mentions for Bionano Genomics. MindWalk's average media sentiment score of 0.52 beat Bionano Genomics' score of 0.00 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNGO or HBIO?

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. Bionano Genomics' average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bionano Genomics (BNGO) Competitors

$1.69 -0.01 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.02 (+0.89%)

As of 07:57 PM Eastern

Compare

BNGO vs. CSBR, RPID, IBAC, HYFT, and HBIO

Should you buy Bionano Genomics stock or one of its competitors? Bionano Genomics's main competitors and comparable companies include Champions Oncology (CSBR), Rapid Micro Biosystems (RPID), IB Acquisition (IBAC), MindWalk (HYFT), and Harvard Bioscience (HBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bionano Genomics compare to Champions Oncology?

Bionano Genomics (NASDAQ:BNGO) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Bionano Genomics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Champions Oncology has a net margin of -1.82% compared to Bionano Genomics' net margin of -106.58%. Champions Oncology's return on equity of -25.77% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Champions Oncology	-1.82%	-25.77%	-3.71%

Bionano Genomics presently has a consensus target price of $6.00, suggesting a potential upside of 255.03%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. Bionano Genomics' average media sentiment score of 0.00 equaled Champions Oncology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Champions Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Champions Oncology has higher revenue and earnings than Bionano Genomics. Champions Oncology is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.70	-$26.40M	-$3.02	N/A
Champions Oncology	$59.42M	1.14	-$1.17M	-$0.08	N/A

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by insiders. Comparatively, 46.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Champions Oncology beats Bionano Genomics on 9 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to Rapid Micro Biosystems?

Rapid Micro Biosystems (NASDAQ:RPID) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Bionano Genomics has lower revenue, but higher earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59M	1.66	-$47.12M	-$1.12	N/A
Bionano Genomics	$28.51M	0.70	-$26.40M	-$3.02	N/A

Rapid Micro Biosystems has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Rapid Micro Biosystems currently has a consensus target price of $6.00, suggesting a potential upside of 440.54%. Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 255.03%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bionano Genomics has a net margin of -106.58% compared to Rapid Micro Biosystems' net margin of -145.56%. Bionano Genomics' return on equity of -78.78% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Bionano Genomics	-106.58%	-78.78%	-48.54%

In the previous week, Rapid Micro Biosystems and Rapid Micro Biosystems both had 2 articles in the media. Rapid Micro Biosystems' average media sentiment score of 0.00 equaled Bionano Genomics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapid Micro Biosystems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Rapid Micro Biosystems beats Bionano Genomics on 8 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to IB Acquisition?

Bionano Genomics (NASDAQ:BNGO) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 255.03%. Given Bionano Genomics' stronger consensus rating and higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. IB Acquisition's average media sentiment score of 0.36 beat Bionano Genomics' score of 0.00 indicating that IB Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IB Acquisition has lower revenue, but higher earnings than Bionano Genomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.70	-$26.40M	-$3.02	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

IB Acquisition has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. IB Acquisition's return on equity of 0.00% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
IB Acquisition	N/A	N/A	N/A

11.4% of Bionano Genomics shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Bionano Genomics beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

How does Bionano Genomics compare to MindWalk?

Bionano Genomics (NASDAQ:BNGO) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, MindWalk had 5 more articles in the media than Bionano Genomics. MarketBeat recorded 7 mentions for MindWalk and 2 mentions for Bionano Genomics. MindWalk's average media sentiment score of 0.52 beat Bionano Genomics' score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MindWalk has lower revenue, but higher earnings than Bionano Genomics. MindWalk is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.70	-$26.40M	-$3.02	N/A
MindWalk	$11.24M	5.65	-$10.11M	-$0.26	N/A

Bionano Genomics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Bionano Genomics currently has a consensus target price of $6.00, suggesting a potential upside of 255.03%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 267.65%. Given MindWalk's stronger consensus rating and higher possible upside, analysts plainly believe MindWalk is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

MindWalk has a net margin of -105.11% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
MindWalk	-105.11%	-133.26%	-77.78%

Summary

MindWalk beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.

How does Bionano Genomics compare to Harvard Bioscience?

Bionano Genomics (NASDAQ:BNGO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. Bionano Genomics' average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bionano Genomics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Bionano Genomics presently has a consensus price target of $6.00, suggesting a potential upside of 255.03%. Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 15.84%. Given Bionano Genomics' higher probable upside, equities research analysts plainly believe Bionano Genomics is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bionano Genomics has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.70	-$26.40M	-$3.02	N/A
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A

Harvard Bioscience has a net margin of -11.86% compared to Bionano Genomics' net margin of -106.58%. Harvard Bioscience's return on equity of -33.13% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Summary

Harvard Bioscience beats Bionano Genomics on 7 of the 12 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.43M	$10.52B	$7.33B	$13.29B
Dividend Yield	N/A	1.45%	2.52%	12.57%
P/E Ratio	-0.56	75.66	274.40	25.75
Price / Sales	0.70	109.39	639.66	87.10
Price / Cash	N/A	27.90	77.80	52.76
Price / Book	0.39	6.06	10.52	6.34
Net Income	-$26.40M	$56.67B	$3.49B	$360.00M
7 Day Performance	-2.87%	3.74%	-1.08%	-0.11%
1 Month Performance	38.52%	4.13%	-3.39%	-3.42%
1 Year Performance	-3.98%	37.40%	15.08%	5.46%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	2.7706 of 5 stars	$1.69 -0.6%	$6.00 +255.0%	+1.2%	$21.43M	$28.51M	N/A	97	News Coverage
CSBR Champions Oncology	0.3525 of 5 stars	$4.87 -4.6%	N/A	-24.4%	$67.91M	$60.66M	N/A	143
RPID Rapid Micro Biosystems	1.9061 of 5 stars	$1.17 -0.2%	$6.00 +413.7%	-65.8%	$58.69M	$35.18M	N/A	200
IBAC IB Acquisition	N/A	$10.93 +0.1%	N/A	+6.4%	$54.69M	N/A	N/A	N/A	News Coverage
HYFT MindWalk	3.242 of 5 stars	$1.13 -15.4%	$5.00 +344.4%	N/A	$52.55M	$15.56M	N/A	80	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. CSBR, RPID, IBAC, HYFT, and HBIO

How does Bionano Genomics compare to Champions Oncology?

Summary

How does Bionano Genomics compare to Rapid Micro Biosystems?

Summary

How does Bionano Genomics compare to IB Acquisition?

Summary

How does Bionano Genomics compare to MindWalk?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. CSBR, RPID, IBAC, HYFT, and HBIO

How does Bionano Genomics compare to Champions Oncology?

Which has more risk and volatility, BNGO or CSBR?

Is BNGO or CSBR more profitable?

Do analysts rate BNGO or CSBR?

Does the media prefer BNGO or CSBR?

Which has better earnings & valuation, BNGO or CSBR?

Do insiders and institutionals have more ownership in BNGO or CSBR?

Summary

How does Bionano Genomics compare to Rapid Micro Biosystems?

Which has preferable valuation and earnings, RPID or BNGO?

Which has more volatility & risk, RPID or BNGO?

Do analysts rate RPID or BNGO?

Is RPID or BNGO more profitable?

Does the media favor RPID or BNGO?

Do insiders & institutionals hold more shares of RPID or BNGO?

Summary

How does Bionano Genomics compare to IB Acquisition?

Do analysts rate BNGO or IBAC?

Does the media refer more to BNGO or IBAC?

Which has stronger earnings & valuation, BNGO or IBAC?

Is BNGO or IBAC more profitable?

Do institutionals and insiders hold more shares of BNGO or IBAC?

Summary

How does Bionano Genomics compare to MindWalk?

Does the media refer more to BNGO or HYFT?

Do institutionals & insiders hold more shares of BNGO or HYFT?

Which has better valuation & earnings, BNGO or HYFT?

Which has more risk & volatility, BNGO or HYFT?

Do analysts rate BNGO or HYFT?

Is BNGO or HYFT more profitable?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Does the media refer more to BNGO or HBIO?

Do insiders & institutionals hold more shares of BNGO or HBIO?

Which has more volatility & risk, BNGO or HBIO?

Do analysts rate BNGO or HBIO?

Which has higher valuation and earnings, BNGO or HBIO?

Is BNGO or HBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools